Tirzepatide (Mounjaro/Zepbound)
A dual GIP/GLP-1 receptor agonist showing the highest weight loss results of any medication, with average losses exceeding 20%.
Overview
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Approved as Mounjaro for diabetes and Zepbound for weight management, it has shown superior weight loss results compared to semaglutide in clinical trials, with some participants losing over 25% of body weight.
How It Works
Tirzepatide activates both GIP and GLP-1 receptors, providing complementary mechanisms for weight loss. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation enhances insulin sensitivity and may improve fat metabolism. The dual action produces greater weight loss than GLP-1 agonists alone.
Benefits
Potential Side Effects
Dosage Information
Zepbound: Started at 2.5mg weekly, escalated every 4 weeks to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg weekly based on response and tolerability.
Administration
Subcutaneous injection (once weekly)
Rating
4.8 / 5.0
Category
Weight Loss Hormones
Common Symptoms
JoinFridays
Starting at $117/month
Shed
10% off first month
TrimRx
Starting at $147/month
Common Questions
Find a Provider for Tirzepatide (Mounjaro/Zepbound)
Compare top providers offering this treatment.
Compare Providers